Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.
The FDA removes a partial clinical hold for Innate’s lacutamab trials following an investigation of a patient’s death.
The MHRA gave Bristol Myers Squibb’s Opdualag marketing authorisation for advanced melanoma as part of Project Orbis.
ARTBIO is developing a proprietary radiotherapy manufacturing technology to overcome distribution and supply chain challenges.
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
Give your business an edge with our leading industry insights.
The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.
Kronos Bio is prioritising its multiple myeloma therapy after reviewing negative Phase Ib AML data for lanraplenib.
Experts discussed the potential impacts of climate change on the pharma supply chain and how companies can prepare for them.
Ironwood Pharmaceuticals completed an acquisition of the gastrointestinal disease company VectivBio.
Pliant Therapeutics doubles down on enrolment for a Phase IIb IPF trial as other industry players also investigate new IPF therapies.